Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free ABCL Stock Alerts

AbCellera Biologics (ABCL) Financials

AbCellera Biologics logo
$4.09 -0.31 (-7.05%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$4.12 +0.03 (+0.73%)
As of 05/15/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for AbCellera Biologics

Annual Income Statements for AbCellera Biologics

This table shows AbCellera Biologics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.21 119 153 159 -146 -163 -146
Consolidated Net Income / (Loss)		 -2.21 119 153 159 -146 -163 -146
Net Income / (Loss) Continuing Operations		 -2.21 119 153 159 -146 -163 -146
Total Pre-Tax Income 		-2.21 158 219 239 -174 -200 -178
Total Operating Income		 -4.12 156 204 217 -237 -315 -217
Total Gross Profit		 12 233 375 485 38 29 75
Total Revenue		 12 233 375 485 38 29 75
Operating Revenue		 12 233 375 485 38 29 75
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 16 69 171 269 275 344 292
Selling, General & Admin Expense		 2.75 12 42 55 75 85 83
Research & Development Expense		 10 29 62 108 176 167 187
Depreciation Expense		 1.60 4.84 14 28 24 91 22
Total Other Income / (Expense), net		 1.91 -6.52 15 23 63 114 40
Interest & Investment Income		 0.16 0.29 3.33 16 42 38 28
Other Income / (Expense), net		 1.75 -6.81 11 6.51 21 76 11
Income Tax Expense		 0.00 39 66 81 -28 -38 -31
Basic Earnings per Share		 ($0.01) $0.53 $0.56 $0.56 ($0.51) ($0.55) ($0.49)
Weighted Average Basic Shares Outstanding		 151.33M 159.20M 275.76M 285.06M 289.17M 294.33M 298.71M
Diluted Earnings per Share		 ($0.01) $0.45 $0.48 $0.50 ($0.51) ($0.55) ($0.49)
Weighted Average Diluted Shares Outstanding		 151.33M 263.13M 318.29M 314.83M 289.17M 294.33M 298.71M
Weighted Average Basic & Diluted Shares Outstanding		 - - 283.92M 287.69M 292.78M 297.99M 303.16M

Quarterly Income Statements for AbCellera Biologics

This table shows AbCellera Biologics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -28 -48 -41 -37 -51 -35 -46 -35 -57 -8.95 -43
Consolidated Net Income / (Loss)		 -29 -47 -41 -37 -51 -34 -46 -35 -57 -8.95 -43
Net Income / (Loss) Continuing Operations		 -29 -47 -41 -37 -51 -34 -46 -35 -57 -8.95 -43
Total Pre-Tax Income 		-39 -49 -43 -48 -63 -47 -53 -36 -69 -19 -50
Total Operating Income		 -55 -66 -55 -93 -94 -73 -63 -50 -76 -29 -58
Total Gross Profit		 6.60 9.18 9.95 7.32 6.51 5.05 4.24 17 8.96 45 8.32
Total Revenue		 6.60 9.18 9.95 7.32 6.51 5.05 4.24 17 8.96 45 8.32
Operating Revenue		 6.60 9.18 9.95 7.32 6.51 5.05 4.24 17 8.96 45 8.32
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 61 75 65 101 100 78 67 67 85 73 66
Selling, General & Admin Expense		 14 16 17 20 19 16 19 19 22 26 12
Research & Development Expense		 38 49 39 41 41 46 42 39 55 50 47
Depreciation Expense		 5.74 7.54 4.84 37 37 13 5.33 5.47 5.25 6.12 6.84
Total Other Income / (Expense), net		 16 17 12 45 31 26 9.68 13 7.51 9.08 7.98
Interest & Investment Income		 11 11 10 9.80 9.60 8.67 5.52 7.59 6.77 5.92 3.64
Other Income / (Expense), net		 4.87 6.48 1.75 35 21 17 4.15 5.65 0.75 3.16 4.34
Income Tax Expense		 -11 -1.45 -2.14 -11 -12 -13 -7.36 -1.62 -12 -11 -6.37
Basic Earnings per Share		 ($0.10) ($0.16) ($0.14) ($0.13) ($0.17) ($0.11) ($0.15) ($0.12) ($0.19) ($0.03) ($0.14)
Weighted Average Basic Shares Outstanding		 289.50M 289.17M 292.72M 294.22M 294.85M 294.33M 297.69M 298.51M 298.88M 298.71M 303.07M
Diluted Earnings per Share		 ($0.10) ($0.16) ($0.14) ($0.13) ($0.17) ($0.11) ($0.15) ($0.12) ($0.19) ($0.03) ($0.14)
Weighted Average Diluted Shares Outstanding		 289.50M 289.17M 292.72M 294.22M 294.85M 294.33M 297.69M 298.51M 298.88M 298.71M 303.07M
Weighted Average Basic & Diluted Shares Outstanding		 290.17M 292.78M 294.05M 294.67M 295.37M 297.99M 298.48M 298.83M 299.34M 303.16M 305.38M

Annual Cash Flow Statements for AbCellera Biologics

This table details how cash moves in and out of AbCellera Biologics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -2.89 587 -93 -86 -254 23 -28
Net Cash From Operating Activities		 2.69 23 245 277 -44 -109 -131
Net Cash From Continuing Operating Activities		 2.69 23 245 277 -44 -109 -131
Net Income / (Loss) Continuing Operations		 -2.21 119 153 159 -146 -163 -146
Consolidated Net Income / (Loss)		 -2.21 119 153 159 -146 -163 -146
Depreciation Expense		 1.60 2.32 4.40 8.95 13 13 18
Amortization Expense		 0.24 2.95 13 24 18 84 10
Non-Cash Adjustments To Reconcile Net Income		 1.08 13 34 56 58 -17 57
Changes in Operating Assets and Liabilities, net		 1.97 -115 40 30 13 -26 -71
Net Cash From Investing Activities		 -5.78 -120 -332 -353 -221 121 88
Net Cash From Continuing Investing Activities		 -5.78 -120 -332 -353 -221 121 88
Purchase of Property, Plant & Equipment		 -4.00 -9.67 -58 -71 -77 -78 -43
Acquisitions		 0.00 -112 -42 -28 -14 -20 -7.14
Purchase of Investments		 0.00 1.78 -292 -781 -1,067 -754 -453
Sale and/or Maturity of Investments		 -1.78 0.00 28 511 911 938 539
Other Investing Activities, net		 0.00 0.00 33 16 25 36 51
Net Cash From Financing Activities		 0.20 684 -3.89 -1.63 10 13 14
Net Cash From Continuing Financing Activities		 0.20 684 -3.89 -1.63 10 13 14
Other Financing Activities, net		 0.03 90 -3.89 -1.63 10 13 14
Effect of Exchange Rate Changes		 0.00 - -1.43 -9.60 0.59 -2.62 1.10

Quarterly Cash Flow Statements for AbCellera Biologics

This table details how cash moves in and out of AbCellera Biologics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -7.33 -39 -9.75 25 -22 30 2.94 -67 -9.28 45 -51
Net Cash From Operating Activities		 -0.11 -20 -42 -30 -29 -8.00 -12 -32 -53 -35 -34
Net Cash From Continuing Operating Activities		 -0.11 -20 -42 -30 -29 -8.00 -12 -32 -53 -35 -34
Net Income / (Loss) Continuing Operations		 -29 -47 -41 -37 -51 -34 -46 -35 -57 -8.95 -43
Consolidated Net Income / (Loss)		 -29 -47 -41 -37 -51 -34 -46 -35 -57 -8.95 -43
Depreciation Expense		 3.06 3.88 3.16 3.45 3.83 2.10 4.41 4.54 4.31 5.18 5.92
Amortization Expense		 4.35 5.23 3.61 35 34 12 2.20 2.52 2.93 2.74 2.74
Non-Cash Adjustments To Reconcile Net Income		 20 11 19 -23 7.55 -20 17 12 15 13 14
Changes in Operating Assets and Liabilities, net		 0.80 7.76 -27 -8.04 -24 33 10 -17 -18 -46 -13
Net Cash From Investing Activities		 -13 -24 30 52 3.70 36 7.94 -32 36 75 -25
Net Cash From Continuing Investing Activities		 -13 -24 30 52 3.70 36 7.94 -32 36 75 -25
Purchase of Property, Plant & Equipment		 -20 -14 -24 -20 -19 -16 -11 -13 -8.93 -9.84 -3.83
Purchase of Investments		 -216 -284 -254 -168 -177 -155 -172 -135 -36 -112 -166
Sale and/or Maturity of Investments		 220 268 307 233 197 202 190 113 83 153 144
Other Investing Activities, net		 7.33 10 7.17 13 9.40 6.56 1.02 5.43 0.92 44 1.36
Net Cash From Financing Activities		 6.63 3.77 2.83 2.65 3.15 4.14 5.97 -3.38 7.37 4.12 7.19
Net Cash From Continuing Financing Activities		 6.63 3.77 2.83 2.65 3.15 4.14 5.97 -3.38 7.37 4.12 7.19
Other Financing Activities, net		 0.07 10 2.83 0.28 0.04 12 5.97 -3.38 7.37 4.12 7.19
Effect of Exchange Rate Changes		 -1.06 1.07 -0.78 -0.04 0.37 -2.16 0.59 0.76 -0.54 0.29 -0.04

Annual Balance Sheets for AbCellera Biologics

This table presents AbCellera Biologics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1,006 1,319 1,541 1,488 1,361 1,357
Total Current Assets		 813 930 1,025 872 751 728
Cash & Equivalents		 594 476 387 133 156 129
Restricted Cash		 - 25 25 25 25 25
Short-Term Investments		 0.00 247 500 627 469 405
Accounts Receivable		 213 161 39 31 34 58
Other Current Assets		 5.97 21 75 56 67 111
Plant, Property, & Equipment, net		 18 112 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 174 277 515 616 609 629
Long-Term Investments		 19 50 73 66 82 63
Goodwill		 32 48 48 48 48 48
Intangible Assets		 115 148 132 120 42 38
Other Noncurrent Operating Assets		 8.39 31 264 382 437 480
Total Liabilities & Shareholders' Equity		 1,006 1,319 1,541 1,488 1,361 1,357
Total Liabilities		 175 293 308 336 304 390
Total Current Liabilities		 103 121 118 119 77 64
Accounts Payable		 20 32 52 50 55 51
Current Deferred Revenue		 6.59 7.54 22 19 14 14
Total Noncurrent Liabilities		 72 172 189 217 228 326
Other Noncurrent Operating Liabilities		 45 107 137 178 218 326
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 831 1,026 1,233 1,152 1,056 967
Total Preferred & Common Equity		 831 1,026 1,233 1,152 1,056 967
Total Common Equity		 831 1,026 1,233 1,152 1,056 967
Common Stock		 716 758 808 874 944 1,001
Retained Earnings		 114 268 426 280 117 -29
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.28 -1.39 -1.72 -4.38 -4.23

Quarterly Balance Sheets for AbCellera Biologics

This table presents AbCellera Biologics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 1,552 1,498 1,537 1,512 1,463 1,412 1,393 1,344 1,402 1,356 1,307
Total Current Assets		 1,046 941 931 920 814 772 743 765 742 695 665
Cash & Equivalents		 372 193 180 172 124 148 127 159 92 83 77
Restricted Cash		 25 25 25 25 25 25 25 25 25 25 25
Short-Term Investments		 496 603 616 613 574 522 516 446 461 413 428
Accounts Receivable		 106 20 46 37 34 36 31 40 47 41 37
Other Current Assets		 46 99 64 71 57 40 43 95 117 133 98
Plant, Property, & Equipment, net		 201 233 260 277 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 306 324 347 315 649 641 650 579 660 661 643
Long-Term Investments		 67 58 59 63 72 76 84 82 90 93 65
Goodwill		 48 48 48 48 48 48 48 48 48 48 48
Intangible Assets		 143 129 127 124 119 86 53 41 40 39 37
Other Noncurrent Operating Assets		 49 90 113 81 411 431 465 409 481 480 492
Total Liabilities & Shareholders' Equity		 1,552 1,498 1,537 1,512 1,463 1,412 1,393 1,344 1,402 1,356 1,307
Total Liabilities		 302 289 342 329 333 302 315 321 395 392 369
Total Current Liabilities		 106 90 119 110 105 70 80 75 67 69 47
Accounts Payable		 26 32 52 36 43 44 54 48 50 53 40
Current Deferred Revenue		 6.82 12 8.54 18 11 6.40 5.58 19 17 16 7.74
Total Noncurrent Liabilities		 196 200 223 219 228 231 235 246 328 323 322
Other Noncurrent Operating Liabilities		 162 141 163 170 189 201 214 222 306 308 322
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,250 1,209 1,195 1,183 1,130 1,111 1,078 1,023 1,007 964 938
Total Preferred & Common Equity		 1,250 1,209 1,195 1,183 1,130 1,111 1,078 1,023 1,007 964 938
Total Common Equity		 1,250 1,209 1,195 1,183 1,130 1,111 1,078 1,023 1,007 964 938
Common Stock		 795 824 841 857 893 911 928 959 973 987 1,013
Retained Earnings		 456 386 356 327 239 202 151 71 37 -21 -73
Accumulated Other Comprehensive Income / (Loss)		 -0.72 -2.02 -1.90 -1.46 -1.82 -2.07 -1.23 -7.00 -2.66 -2.70 -2.42

Annual Metrics And Ratios for AbCellera Biologics

This table displays calculated financial ratios and metrics derived from AbCellera Biologics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 1,907.88% 60.92% 29.38% -92.17% -24.17% 160.56%
EBITDA Growth		 0.00% 29,867.05% 50.86% 9.89% -172.38% 23.47% -24.83%
EBIT Growth		 0.00% 6,406.85% 44.63% 3.34% -196.98% -10.45% 13.79%
NOPAT Growth		 0.00% 4,179.26% 21.76% 0.28% -215.68% -32.70% 31.03%
Net Income Growth		 0.00% 5,478.47% 29.05% 3.29% -192.35% -11.24% 10.10%
EPS Growth		 0.00% 4,600.00% 6.67% 4.17% -202.00% -7.84% 10.91%
Operating Cash Flow Growth		 0.00% 742.24% 977.94% 13.40% -115.82% -147.41% -20.95%
Free Cash Flow Firm Growth		 0.00% 0.00% 209.14% -18.56% -322.85% 10.50% 17.03%
Invested Capital Growth		 0.00% 0.00% 8.60% 17.22% 19.69% -5.70% 4.30%
Revenue Q/Q Growth		 0.00% 0.00% -13.63% -19.52% -24.54% -12.53% 112.69%
EBITDA Q/Q Growth		 0.00% 0.00% -22.51% -30.18% -16.29% 5.88% 11.98%
EBIT Q/Q Growth		 0.00% 0.00% -24.48% -35.22% -10.03% 1.68% 12.74%
NOPAT Q/Q Growth		 0.00% 0.00% -30.84% -38.85% -13.53% -2.18% 16.91%
Net Income Q/Q Growth		 0.00% 0.00% -27.10% -36.17% -13.36% 7.36% 14.72%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -37.50% -13.33% 8.33% 14.04%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -6.85% 20.73% -760.20% 9.66% -25.58%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 31.28% -20.05% -0.79% 11.06%
Invested Capital Q/Q Growth		 0.00% 0.00% 52.17% -9.08% -3.23% -4.28% -1.30%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -4.47% 66.26% 62.12% 52.76% -487.53% -492.04% -235.74%
Operating Margin		 -35.45% 66.92% 54.48% 44.60% -623.82% -1,091.69% -288.98%
EBIT Margin		 -20.38% 64.00% 57.52% 45.94% -568.77% -828.45% -274.10%
Profit (Net Income) Margin		 -19.04% 51.00% 40.90% 32.66% -385.00% -564.83% -194.88%
Tax Burden Percent		 100.00% 75.34% 70.03% 66.30% 84.12% 81.27% 82.44%
Interest Burden Percent		 93.45% 105.77% 101.54% 107.21% 80.47% 83.89% 86.24%
Effective Tax Rate		 0.00% 24.66% 29.97% 33.70% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 101.98% 59.53% 52.79% -51.51% -64.56% -44.91%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 101.53% 58.03% 51.04% -53.76% -72.10% -45.74%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -73.34% -42.99% -38.75% 39.23% 49.82% 30.44%
Return on Equity (ROE)		 0.00% 28.64% 16.53% 14.03% -12.27% -14.75% -14.47%
Cash Return on Invested Capital (CROIC)		 0.00% -98.02% 51.29% 36.94% -69.43% -58.70% -49.12%
Operating Return on Assets (OROA)		 0.00% 14.84% 18.57% 15.60% -14.28% -16.77% -15.16%
Return on Assets (ROA)		 0.00% 11.83% 13.21% 11.09% -9.67% -11.43% -10.78%
Return on Common Equity (ROCE)		 0.00% 28.64% 16.53% 14.03% -12.27% -14.75% -14.47%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 14.32% 14.96% 12.85% -12.70% -15.42% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.88 118 143 144 -166 -220 -152
NOPAT Margin		 -24.82% 50.42% 38.15% 29.57% -436.67% -764.18% -202.28%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.45% 1.50% 1.75% 2.26% 7.53% 0.83%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 11.24% -13.80% -20.71% -15.72%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 23.67% 5.11% 11.15% 11.43% 160.42% 252.18% 110.79%
R&D to Revenue		 87.09% 12.61% 16.54% 22.22% 461.95% 580.10% 248.68%
Operating Expenses to Revenue		 135.45% 29.51% 45.52% 55.40% 723.82% 1,191.69% 388.98%
Earnings before Interest and Taxes (EBIT)		 -2.37 149 216 223 -216 -239 -206
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.52 154 233 256 -185 -142 -177
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 1.17 3.93 2.35 1.44 0.82 1.06
Price to Tangible Book Value (P/TBV)		 0.00 1.42 4.85 2.75 1.68 0.90 1.16
Price to Revenue (P/Rev)		 41.59 4.17 10.73 5.97 43.57 30.02 13.63
Price to Earnings (P/E)		 0.00 8.17 26.24 18.28 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 12.24% 3.81% 5.47% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 1.61 12.99 6.67 2.44 0.42 1.16
Enterprise Value to Revenue (EV/Rev)		 0.00 1.59 8.67 4.03 22.51 4.88 5.36
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 2.41 13.95 7.65 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 2.49 15.06 8.78 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 3.16 22.71 13.64 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 16.39 13.29 7.06 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 26.36 19.50 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.02 0.02 0.04 0.04 0.01 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.72 -0.74 -0.76 -0.73 -0.69 -0.67
Leverage Ratio		 0.00 1.21 1.25 1.27 1.27 1.29 1.34
Compound Leverage Factor		 0.00 1.28 1.27 1.36 1.02 1.08 1.16
Debt to Total Capital		 0.00% 1.59% 2.19% 3.46% 4.20% 0.76% 0.00%
Short-Term Debt to Total Capital		 0.00% 1.59% 2.19% 3.46% 4.20% 0.76% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 98.41% 97.81% 96.54% 95.80% 99.24% 100.00%
Debt to EBITDA		 0.00 0.09 0.10 0.17 -0.27 -0.06 0.00
Net Debt to EBITDA		 0.00 -3.88 -3.33 -3.67 4.32 5.11 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.11 0.16 0.31 -0.30 -0.04 0.00
Net Debt to NOPAT		 0.00 -5.10 -5.42 -6.55 4.82 3.29 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 5.06 10.10 7.54 3.38 1.86 1.69
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 7.86 7.70 8.67 7.33 9.81 11.32
Quick Ratio		 0.00 7.80 7.32 7.82 6.65 8.60 9.21
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -113 123 100 -224 -200 -166
Operating Cash Flow to CapEx		 67.40% 234.57% 418.44% 392.53% -57.02% -138.47% -306.96%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.23 0.32 0.34 0.03 0.02 0.06
Accounts Receivable Turnover		 0.00 1.09 2.01 4.87 1.10 0.90 1.63
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 13.01 5.79 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 333.82 181.82 74.88 332.04 406.40 223.26
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 333.82 181.82 74.88 332.04 406.40 223.26
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 231 250 293 351 331 345
Invested Capital Turnover		 0.00 2.02 1.56 1.79 0.12 0.08 0.22
Increase / (Decrease) in Invested Capital		 0.00 231 20 43 58 -20 14
Enterprise Value (EV)		 0.00 372 3,251 1,958 856 141 402
Market Capitalization		 483 972 4,027 2,898 1,657 865 1,024
Book Value per Share		 $0.00 $5.22 $3.64 $4.31 $3.97 $3.58 $3.23
Tangible Book Value per Share		 $0.00 $4.30 $2.95 $3.68 $3.39 $3.27 $2.94
Total Capital		 0.00 844 1,049 1,277 1,203 1,064 967
Total Debt		 0.00 13 23 44 50 8.09 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -600 -775 -940 -801 -725 -621
Capital Expenditures (CapEx)		 4.00 9.67 58 71 77 78 43
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 129 84 40 18 32 105
Debt-free Net Working Capital (DFNWC)		 0.00 723 832 951 803 683 664
Net Working Capital (NWC)		 0.00 710 809 907 753 675 664
Net Nonoperating Expense (NNE)		 -0.67 -1.36 -10 -15 -20 -57 -5.56
Net Nonoperating Obligations (NNO)		 0.00 -600 -775 -940 -801 -725 -621
Total Depreciation and Amortization (D&A)		 1.85 5.27 17 33 31 97 29
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 55.38% 22.41% 8.22% 46.97% 111.79% 139.89%
Debt-free Net Working Capital to Revenue		 0.00% 310.20% 221.76% 195.99% 2,112.94% 2,368.28% 883.73%
Net Working Capital to Revenue		 0.00% 304.45% 215.65% 186.88% 1,980.20% 2,340.23% 883.73%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.56 $0.56 ($0.51) ($0.55) ($0.49)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 275.76M 285.06M 289.17M 294.33M 298.71M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.48 $0.50 ($0.51) ($0.55) ($0.49)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 318.29M 314.83M 289.17M 294.33M 298.71M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 283.92M 287.69M 292.78M 297.99M 303.16M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.88 118 143 144 -166 -220 -152
Normalized NOPAT Margin		 -24.82% 50.42% 38.15% 29.57% -436.67% -764.18% -202.28%
Pre Tax Income Margin		 -19.04% 67.69% 58.41% 49.26% -457.67% -695.02% -236.39%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for AbCellera Biologics

This table displays calculated financial ratios and metrics derived from AbCellera Biologics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 303,160,487.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 303,160,487.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.14
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -93.49% -57.40% -18.36% -27.18% -1.39% -44.99% -57.45% 133.29% 37.62% 788.37% 96.34%
EBITDA Growth		 -189.21% -106.01% 8.67% 51.96% 20.34% 17.57% -17.35% -84.83% -101.23% 57.93% 14.21%
EBIT Growth		 -221.90% -49.47% 8.22% -18.87% -44.42% 6.84% -14.84% 24.23% -4.57% 54.20% 9.10%
NOPAT Growth		 -278.17% -74.85% 15.38% -81.86% -70.64% -10.14% -14.15% 46.94% 18.56% 60.72% 8.20%
Net Income Growth		 -207.46% -57.73% -1.25% -20.97% -78.63% 27.44% -12.34% 5.97% -11.76% 73.85% 5.38%
EPS Growth		 -225.00% -60.00% 0.00% -18.18% -70.00% 31.25% -7.14% 7.69% -11.76% 72.73% 6.67%
Operating Cash Flow Growth		 99.92% -163.44% 5.34% -250.56% -27,147.17% 59.21% 72.30% -8.14% -82.10% -334.29% -190.14%
Free Cash Flow Firm Growth		 42.48% -49.57% -0.41% 79.87% 38.09% 70.28% 143.41% 74.88% -17.87% -10.76% -376.23%
Invested Capital Growth		 12.45% 19.69% 3.88% -2.87% -4.65% -5.70% -17.28% -5.83% 1.15% 4.30% 7.23%
Revenue Q/Q Growth		 -34.38% 39.08% 8.46% -26.43% -11.14% -22.41% -16.12% 303.40% -47.58% 400.88% -81.46%
EBITDA Q/Q Growth		 -2.60% -18.43% 8.08% 56.99% -70.12% -22.56% -30.85% 32.25% -85.21% 74.38% -154.43%
EBIT Q/Q Growth		 -2.53% -19.10% 10.78% -9.11% -24.57% 23.17% -9.98% 28.02% -71.92% 66.35% -109.21%
NOPAT Q/Q Growth		 -6.81% -20.34% 16.90% -70.24% -0.22% 22.32% 13.88% 20.87% -53.83% 62.53% -101.26%
Net Income Q/Q Growth		 6.28% -64.80% 13.87% 9.06% -38.39% 33.06% -33.36% 23.88% -64.48% 84.34% -382.56%
EPS Q/Q Growth		 9.09% -60.00% 12.50% 7.14% -30.77% 35.29% -36.36% 20.00% -58.33% 84.21% -366.67%
Operating Cash Flow Q/Q Growth		 -100.53% -18,400.94% -112.68% 28.15% 3.62% 72.30% -44.43% -180.46% -62.31% 33.94% 3.51%
Free Cash Flow Firm Q/Q Growth		 71.11% -32.31% 49.19% -3.63% 11.14% 36.48% 174.22% -159.96% -316.99% 40.31% -85.10%
Invested Capital Q/Q Growth		 -1.96% -3.23% 10.09% -7.02% -3.75% -4.28% -3.42% 5.85% 3.38% -1.30% -0.71%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -645.66% -549.80% -465.96% -272.44% -521.59% -823.87% -1,285.24% -215.85% -762.67% -39.02% -535.48%
Operating Margin		 -831.79% -719.70% -551.48% -1,276.17% -1,439.42% -1,440.98% -1,479.58% -290.24% -851.79% -63.72% -691.75%
EBIT Margin		 -757.93% -649.05% -533.94% -791.86% -1,110.11% -1,099.17% -1,441.20% -257.18% -843.47% -56.67% -639.57%
Profit (Net Income) Margin		 -433.55% -513.73% -407.98% -504.30% -785.42% -677.56% -1,077.24% -203.27% -637.84% -19.94% -519.12%
Tax Burden Percent		 72.84% 97.01% 95.00% 76.64% 81.60% 73.05% 86.10% 95.55% 83.06% 45.87% 87.14%
Interest Burden Percent		 78.53% 81.59% 80.43% 83.10% 86.71% 84.38% 86.81% 82.72% 91.04% 76.71% 93.15%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -85.57% -59.42% -36.40% -80.92% -93.68% -85.22% -67.75% -19.13% -60.51% -9.90% -115.71%
ROIC Less NNEP Spread (ROIC-NNEP)		 -86.69% -59.32% -36.13% -84.54% -95.54% -87.41% -67.51% -19.13% -59.95% -11.55% -115.26%
Return on Net Nonoperating Assets (RNNOA)		 62.26% 43.29% 24.40% 57.78% 65.58% 60.40% 45.35% 12.82% 39.52% 7.68% 76.29%
Return on Equity (ROE)		 -23.31% -16.14% -12.00% -23.14% -28.10% -24.82% -22.40% -6.31% -20.99% -2.22% -39.41%
Cash Return on Invested Capital (CROIC)		 -54.38% -69.43% -45.71% -48.74% -56.06% -58.70% -44.99% -49.87% -53.69% -49.12% -51.74%
Operating Return on Assets (OROA)		 -24.92% -16.30% -12.91% -17.75% -25.19% -22.25% -23.73% -6.01% -21.68% -3.13% -38.21%
Return on Assets (ROA)		 -14.26% -12.90% -9.86% -11.30% -17.82% -13.72% -17.74% -4.75% -16.39% -1.10% -31.02%
Return on Common Equity (ROCE)		 -23.31% -16.14% -12.00% -23.14% -28.10% -24.82% -22.40% -6.31% -20.99% -2.22% -39.41%
Return on Equity Simple (ROE_SIMPLE)		 -10.92% 0.00% -13.00% -13.80% -16.31% 0.00% -16.41% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -38 -46 -38 -65 -66 -51 -44 -35 -53 -20 -40
NOPAT Margin		 -582.25% -503.79% -386.03% -893.32% -1,007.59% -1,008.68% -1,035.70% -203.17% -596.25% -44.60% -484.22%
Net Nonoperating Expense Percent (NNEP)		 1.12% -0.10% -0.28% 3.62% 1.86% 2.19% -0.24% 0.00% -0.55% 1.64% -0.45%
Return On Investment Capital (ROIC_SIMPLE)		 - -3.84% - - - -4.79% -4.25% -3.45% -5.54% -2.07% -4.29%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 217.75% 174.06% 174.32% 275.73% 294.25% 317.29% 383.14% 111.08% 246.25% 57.91% 148.33%
R&D to Revenue		 574.59% 529.76% 394.69% 558.88% 629.61% 912.58% 1,003.45% 229.53% 614.49% 111.68% 561.18%
Operating Expenses to Revenue		 931.79% 819.70% 651.48% 1,376.17% 1,539.42% 1,540.98% 1,579.58% 390.24% 951.79% 163.72% 791.75%
Earnings before Interest and Taxes (EBIT)		 -50 -60 -53 -58 -72 -55 -61 -44 -76 -25 -53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -43 -50 -46 -20 -34 -42 -54 -37 -68 -18 -45
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.13 1.44 1.16 0.78 0.71 0.82 0.65 1.02 1.56 1.06 1.13
Price to Tangible Book Value (P/TBV)		 1.32 1.68 1.36 0.89 0.78 0.90 0.71 1.11 1.71 1.16 1.24
Price to Revenue (P/Rev)		 26.41 43.57 36.73 26.33 23.24 30.02 28.75 31.14 42.55 13.63 13.36
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.41 2.44 1.48 0.33 0.10 0.42 0.00 1.05 2.54 1.16 1.35
Enterprise Value to Revenue (EV/Rev)		 10.15 22.51 15.96 3.60 1.04 4.88 0.00 10.81 25.17 5.36 5.85
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 76.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.05 0.04 0.05 0.02 0.02 0.01 0.01 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.72 -0.73 -0.68 -0.68 -0.69 -0.69 -0.67 -0.67 -0.66 -0.67 -0.66
Leverage Ratio		 1.26 1.27 1.27 1.28 1.28 1.29 1.30 1.33 1.35 1.34 1.35
Compound Leverage Factor		 0.99 1.04 1.02 1.06 1.11 1.09 1.13 1.10 1.23 1.03 1.26
Debt to Total Capital		 4.36% 4.20% 4.35% 1.77% 1.84% 0.76% 0.85% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 4.36% 4.20% 4.35% 1.77% 1.84% 0.76% 0.85% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 95.64% 95.80% 95.65% 98.23% 98.16% 99.24% 99.15% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.34 -0.27 -0.28 -0.13 -0.13 -0.06 -0.06 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 5.14 4.32 4.11 4.71 4.86 5.11 4.69 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.37 -0.30 -0.32 -0.11 -0.09 -0.04 -0.04 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 5.61 4.82 4.67 3.99 3.39 3.29 3.11 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.29 3.72 3.08 2.42 2.04 2.31 1.80 2.09 2.68 2.13 2.14
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.34 7.33 7.76 10.96 9.34 9.81 10.15 11.07 10.10 11.32 14.05
Quick Ratio		 7.47 6.65 6.98 10.04 8.48 8.60 8.56 8.96 7.81 9.21 11.45
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -79 -104 -53 -55 -49 -31 23 -14 -57 -34 -63
Operating Cash Flow to CapEx		 -0.52% -135.89% -172.78% -149.01% -155.98% -51.18% -108.63% -242.45% -589.09% -352.97% -875.05%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.03 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.06 0.06
Accounts Receivable Turnover		 0.70 1.10 1.32 0.81 0.96 0.90 0.62 0.79 0.97 1.63 2.06
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 519.40 332.04 277.53 451.76 381.03 406.40 587.63 463.28 376.28 223.26 176.87
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 519.40 332.04 277.53 451.76 381.03 406.40 587.63 463.28 376.28 223.26 176.87
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 363 351 387 360 346 331 320 339 350 345 343
Invested Capital Turnover		 0.15 0.12 0.09 0.09 0.09 0.08 0.07 0.09 0.10 0.22 0.24
Increase / (Decrease) in Invested Capital		 40 58 14 -11 -17 -20 -67 -21 3.98 14 23
Enterprise Value (EV)		 511 856 571 119 34 141 -39 355 889 402 463
Market Capitalization		 1,331 1,657 1,314 870 766 865 665 1,024 1,503 1,024 1,058
Book Value per Share		 $4.09 $3.97 $3.86 $3.78 $3.66 $3.58 $3.43 $3.37 $3.23 $3.23 $3.09
Tangible Book Value per Share		 $3.49 $3.39 $3.29 $3.32 $3.32 $3.27 $3.13 $3.08 $2.93 $2.94 $2.81
Total Capital		 1,237 1,203 1,181 1,131 1,098 1,064 1,032 1,007 964 967 938
Total Debt		 54 50 51 20 20 8.09 8.77 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -820 -801 -743 -751 -732 -725 -703 -668 -614 -621 -595
Capital Expenditures (CapEx)		 20 14 24 20 19 16 11 13 8.93 9.84 3.83
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 52 18 37 26 15 32 68 97 106 105 88
Debt-free Net Working Capital (DFNWC)		 863 803 760 721 684 683 698 675 626 664 617
Net Working Capital (NWC)		 809 753 709 701 663 675 690 675 626 664 617
Net Nonoperating Expense (NNE)		 -9.81 0.91 2.18 -28 -14 -17 1.76 0.02 3.72 -11 2.90
Net Nonoperating Obligations (NNO)		 -820 -801 -743 -751 -732 -725 -703 -668 -614 -621 -595
Total Depreciation and Amortization (D&A)		 7.41 9.11 6.77 38 38 14 6.61 7.06 7.24 7.92 8.66
Debt-free, Cash-free Net Working Capital to Revenue		 103.93% 46.97% 104.71% 78.19% 46.70% 111.79% 294.57% 295.19% 299.14% 139.89% 110.56%
Debt-free Net Working Capital to Revenue		 1,713.05% 2,112.94% 2,125.06% 2,181.89% 2,073.70% 2,368.28% 3,021.34% 2,053.60% 1,773.17% 883.73% 779.34%
Net Working Capital to Revenue		 1,606.03% 1,980.20% 1,981.35% 2,121.30% 2,012.36% 2,340.23% 2,983.40% 2,053.60% 1,773.17% 883.73% 779.34%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.10) ($0.16) ($0.14) ($0.13) ($0.17) ($0.11) ($0.15) ($0.12) ($0.19) ($0.03) ($0.14)
Adjusted Weighted Average Basic Shares Outstanding		 289.50M 289.17M 292.72M 294.22M 294.85M 294.33M 297.69M 298.51M 298.88M 298.71M 303.07M
Adjusted Diluted Earnings per Share		 ($0.10) ($0.16) ($0.14) ($0.13) ($0.17) ($0.11) ($0.15) ($0.12) ($0.19) ($0.03) ($0.14)
Adjusted Weighted Average Diluted Shares Outstanding		 289.50M 289.17M 292.72M 294.22M 294.85M 294.33M 297.69M 298.51M 298.88M 298.71M 303.07M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 290.17M 292.78M 294.05M 294.67M 295.37M 297.99M 298.48M 298.83M 299.34M 303.16M 305.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -38 -46 -38 -65 -66 -51 -44 -35 -53 -20 -40
Normalized NOPAT Margin		 -582.25% -503.79% -386.03% -893.32% -1,007.59% -1,008.68% -1,035.70% -203.17% -596.25% -44.60% -484.22%
Pre Tax Income Margin		 -595.18% -529.54% -429.45% -658.02% -962.53% -927.49% -1,251.10% -212.74% -767.93% -43.47% -595.75%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are a concise set of takeaways for AbCellera Biologics (ABCL) based on the quarterly financials provided (latest Q4 2025 and prior four years). Below are the top 10 items, with positives listed first, followed by neutrals, then negatives.

  • Q4 2025 revenue spike: Operating revenue and total revenue reached 44,854,000 USD in Q4 2025, a sharp rise from earlier quarters and a notable quarterly uptick.
  • Major cash inflow from investing activities in Q4 2025: Net cash from continuing investing activities was 75,138,000 USD, driven by the sale/maturity of investments.
  • Improved quarterly cash position in Q4 2025: Net change in cash and equivalents was an increase of 44,800,000 USD for the quarter, signaling improved liquidity that quarter.
  • Modest financing support in Q4 2025: Net cash from financing activities was 4,115,000 USD, providing some financing cushion during the quarter.
  • Strong liquidity snapshot in Q3 2025: At end-Q3 2025, the company held cash of 83,159,000 USD and short-term investments of 412,513,000 USD, with total current assets of 695,140,000 USD, implying a sizable liquidity cushion; there were no short-term debts then.
  • Revenue volatility across quarters: ABCL’s topline has fluctuated (examples include Q3 2025: 8.96M, Q4 2025: 44.85M, Q2 2025: 17.08M, Q1 2025: 4.24M), indicating variability in quarterly demand or recognition.
  • Heavy but ongoing R&D investment: Research & Development expenses run high each quarter (Q4 2025: 50.09M; Q3 2025: 55.03M; Q2 2025: 39.21M; Q1 2025: 42.50M), reflecting a persistent focus on pipeline development.
  • Steady, sizable share count with ongoing losses: Weighted average shares outstanding are in the 298–303 million range across 2025, with basic and diluted earnings per share reported as negative (e.g., Q4 2025 EPS -0.03).
  • Persistent net losses: Net income from continuing operations was negative across recent quarters (Q4 2025 Consolidated Net Income -8.95M; Q3 2025 -57.12M; Q2 2025 -34.73M; Q1 2025 -45.62M).
  • Negative operating income in multiple quarters: Total Operating Income was negative in several periods (Q4 2025: -28.58M; Q3 2025: -76.28M), indicating ongoing operating losses despite revenue entries.
05/17/26 12:22 PM ETAI Generated. May Contain Errors.

AbCellera Biologics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, AbCellera Biologics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

AbCellera Biologics' net income appears to be on an upward trend, with a most recent value of -$146.41 million in 2025, rising from -$2.21 million in 2019. The previous period was -$162.86 million in 2024. Find out what analysts predict for AbCellera Biologics in the coming months.

AbCellera Biologics' total operating income in 2025 was -$217.10 million, based on the following breakdown:
  • Total Gross Profit: $75.13 million
  • Total Operating Expenses: $292.23 million

Over the last 6 years, AbCellera Biologics' total revenue changed from $11.61 million in 2019 to $75.13 million in 2025, a change of 547.0%.

AbCellera Biologics' total liabilities were at $390.05 million at the end of 2025, a 28.1% increase from 2024, and a 122.8% increase since 2020.

In the past 5 years, AbCellera Biologics' cash and equivalents has ranged from $128.51 million in 2025 to $594.12 million in 2020, and is currently $128.51 million as of their latest financial filing in 2025.

Over the last 6 years, AbCellera Biologics' book value per share changed from 0.00 in 2019 to 3.23 in 2025, a change of 323.0%.


Related Companies

Financial statements for NASDAQ:ABCL last updated on 5/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
SpaceX Goes Public. Here's What Happens To Your IRA.
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel